| Literature DB >> 30274320 |
Siraj Sundaran1, Anjali Udayan2, Keerthi Hareendranath3, Basil Eliyas4, Babu Ganesan5, Ashik Hassan6, Rajesh Subash7, Vishnu Palakkal8, Mohammed Saji Salahudeen9.
Abstract
Hospital-based adverse drug reaction (ADR) monitoring and reporting programs intend to identify and quantify the risks associated with the use of medicines. To examine the causality, preventability and severity of ADR in a hospital setting; a prospective cohort study on spontaneous ADR reporting was conducted from December 2015 to May 2016. Incidence of ADRs, causality, type, severity and preventability were assessed using necessary assessment scales. The study included 3157 hospitalized individuals, in whom 51 ADRs were detected among 49 patients. The overall incidence of suspected ADRs was found to be 1.6%. According to the causality assessment, most of the ADRs reported were probable (n = 26, 51.0%), and type A (augmented/pharmacological) reactions (n = 39, 76%) were the most common type of ADR found. The majority of ADRs were moderate to severe (n = 35, 68.6%), of which 37.3% were found to be potentially preventable. Predictability was observed in 28 (54.9%) reported ADRs. The prescribed medicines most frequently associated with ADRs were antibiotics, antiepileptics and antihypertensives. This feasibility study was able to highlight the clinical pharmacist's role in ADR monitoring service and create awareness about the way it could be done to promote safer medication use. Similar ADR reporting programs are necessary to educate and to improve awareness among healthcare professionals in some countries.Entities:
Keywords: ADR; adverse drug reactions; causality; severity; spontaneous reporting
Year: 2018 PMID: 30274320 PMCID: PMC6306913 DOI: 10.3390/pharmacy6040108
Source DB: PubMed Journal: Pharmacy (Basel) ISSN: 2226-4787
Characteristics of the study population (n = 3157).
| Demographic Characteristics | Number of Patients with ADR | Percentage (%) | |
|---|---|---|---|
| Sex * | Male | 21 | 42.9 |
| Female | 28 | 57.1 | |
| Age (years) * | ≤18 | 5 | 10.2 |
| 19–64 | 23 | 46.9 | |
| ≥ 65 | 21 | 42.9 | |
| ADR per patient | At least one | 48 | 98.0 |
| Greater than one | 1 | 2.0 | |
* Chi square test shows not significant at p < 0.05.
Summary of adverse drug reactions based on severity, preventability, predictability, management and outcome.
| Parameter | Frequency ( |
|---|---|
| Classification (Wills and Brown Classification) | |
| Type A-Augmented | 39 (76.5%) |
| Type B-Bugs | 0 |
| Type C-Chemical | 1 (2.0%) |
| Type D-Delivery | 1 (2.0%) |
| Type E-Exit | 0 |
| Type F-Familial | 0 |
| Type G-Genotoxicity | 0 |
| Type H-Hypersensitivity | 10 (19.6%) |
| Type U-Unclassified | 0 |
| Causality (Naranjo’s algorithm scale) | |
| Probable | 26 (51.0%) |
| Possible | 25 (49.0%) |
| Definite | 0 |
| Unlikely | 0 |
| Severity (Modified Hartwig and Siegel scale) | |
| Mild-Level 1 | 0 |
| Mild-Level 2 | 11 (21.6%) |
| Moderate-Level 3 | 25 (49.0%) |
| Moderate-Level 4 (a) | 8 (15.7%) |
| Moderate-Level 4 (b) | 2 (3.9%) |
| Severe-Level 5 | 5 (9.8%) |
| Severe-Level 6 | 0 |
| Severe-Level 7 | 0 |
| Preventability (Modified Schumock and Thornton scale) | |
| Definitely preventable | 15 (29.4%) |
| Probably preventable | 19 (37.3%) |
| Not preventable | 17 (33.3%) |
| Predictability (based on the incidence rate of the reported ADRs as per product information and relevant literatures) | |
| Predictable | 28 (54.9%) |
| Unpredictable | 23 (45.1%) |
| Management | |
| Stopped the medication | 15 (29.4%) |
| Substituted another drug | 15 (29.4%) |
| Reduced the dose | 12 (23.5%) |
| Added another drug | 9 (17.7%) |
| Outcome of management | |
| Recovered | 30 (58.8%) |
| Recovering | 21 (41.2%) |
| Fatal | 0 |
Drug classes commonly associated with adverse drug reactions.
| Drug Class ( | Medication | Reaction Details |
|---|---|---|
| Antibiotic (14, 27.5) | Ciprofloxacin | Redness and itching |
| Metronidazole | Vomiting, Thrombophlebitis | |
| Ofloxacin | Seizure | |
| Amoxicillin + Clavulanic acid | Fever | |
| Cefoperazone + Sulbactam | Inflammation of vein, Diarrhea | |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Nausea | |
| Amoxicillin | Colitis | |
| Cefotaxime | Itching and rash | |
| Ceftazidime + Tobramycin | Itching and rash | |
| Ceftriaxone | Thrombocytosis | |
| Antiepileptic (11, 21.6) | Sodium valproate | Alopecia |
| Carbamazepine | Fatigue, Blurred vision, Ataxia | |
| Clobazam | Memory loss, Hypersomnia | |
| Topiramate | Anorexia | |
| Levetiracetam | Decreased appetite | |
| Oxcarbamazepine | Hypersomnia and fatigue | |
| Antihypertensive (4, 7.8) | Bisoprolol, Carvedilol | Increased breathlessness and QT prolongation |
| Furosemide | Hyponatremia, Hypokalemia | |
| Telmisartan, Cilnidipine | Hypotension | |
| NSAID (3, 5.9) | Ketorolac | Periorbital edema, Redness and itching |
| Mefenamic acid | Gastritis | |
| Antipsychotics (2, 3.9) | Olanzapine + Quetiapine | Extra pyramidal symptoms |
| Quetiapine | Fatigue | |
| Statin (2, 3.9) | Atorvastatin | Myopathy |
| Rosuvastatin | Myopathy | |
| Antifungal (2, 3.9) | Amphotericin B | Renal failure, Diarrhea |
| Anesthetic (3, 5.9) | Bupivacaine | Post spinal headache * |
| Cognition enhancer (1, 2.0) | Cerebroprotein hydrolysate | Itching |
| Antidiabetic (1, 2.0) | Glimepiride | Hypoglycemia |
| Anti-craving agent (1, 2.0) | Acamprosate | Diarrhea |
| Antiplatelet (1, 2.0) | Clopidogrel | Abdominal pain |
| Diagnostic agent (1, 2.0) | Iopromide | Anaphylactic shock |
| Antianginal (1, 2.0) | Isosorbide dinitrate | Hypotension |
| Antineoplastic (1, 2.0) | Rituximab | Shivering and breathing difficulty |
| Others (3, 5.9) | Prazosin | Generalized maculopapular rashes |
| Paracetamol | Nephropathy | |
| Insulin, Furosemide | Hypokalemia |
NSAID = Nonsteroidal anti-inflammatory drugs; * = more than once.